## WHAT IS CLAIMED IS:

- 1. A purified protein comprising a polypeptide sequence that is at least 70% identical to an amino acid sequence selected from the group consisting of:
  - (a) amino acids 1 to 281 of SEQ ID NO:2;
  - (b) amino acids 39 to 281 of SEQ ID NO:2, wherein said polypeptide sequence has a biological activity selected from the group consisting of:
    - (i) binding an antibody specific to the polypeptide of SEQ ID NO:2;
    - (ii) inducing apoptosis of a cell line derived from pathologic tissue; and
    - (iii) inducing apoptosis of T cells.
- 2. The purified protein of claim 1 which comprises a heterologous polypeptide sequence.
- 3. A composition comprising the purified protein of claim 1 and a pharmaceutically acceptable carrier.
- 4. The purified protein of claim 1 wherein said polypeptide sequence is at least 90% identical to amino acids 1 to 281 of SEQ ID NO:2.
- 5. The purified protein of claim 1 wherein said polypeptide sequence is at least 90% identical to amino acids 39 to 281 of SEQ ID NO:2.
- 6. The purified protein of claim 1 wherein said polypeptide sequence is at least 95% identical to amino acids 1 to 281 of SEQ ID NO:2.
- 7. The purified protein of claim 1 wherein said polypeptide sequence is at least 95% identical to amino acids 39 to 281 of SEQ ID NO:2.
- 8. A purified protein comprising a polypeptide sequence of 30 contiguous amino acids of SEQ ID NO:2, wherein said protein has a biological activity selected from the group consisting of:

- (a) binding an antibody specific to the polypeptide of SEQ ID NO:2;
- (b) inducing apoptosis of a cell line derived from pathologic tissue; and
- (c) inducing apoptosis of T cells.
- 9. The purified protein of claim 8 which comprises a polypeptide sequence of 50 contiguous amino acids of SEQ ID NO:2.
- 10. A purified protein comprising a polypeptide sequence that is a fragment of amino acids 1 to 281 of SEQ ID NO:2, wherein said polypeptide sequence has a biological activity selected from the group consisting of:
  - (a) binding an antibody specific to the polypeptide of SEQ ID NO:2;
  - (b) inducing apoptosis of a cell line derived from pathologic tissue; and
  - (c) inducing apoptosis of T cells.
- 11. The purified protein of claim 10, which comprises a heterologous polypeptide sequence.
- 12. A composition comprising the purified protein of claim 10 and a pharmaceutically acceptable carrier.
- 13. A purified protein comprising a polypeptide sequence selected from the group consisting of:
  - (a) the amino acid sequence of the full-length polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97448; and
  - (b) the amino acid sequence of the mature polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97448.
- 14. The purified protein of claim 13, wherein said polypeptide sequence is (a).
- 15. The purified protein of claim 13, wherein said polypeptide sequence is (b).

- 16. The purified protein of claim 13, which comprises a heterologous polypeptide sequence.
- 17. A composition comprising the purified protein of claim 13 and a pharmaceutically acceptable carrier.
- 18. A purified protein comprising a polypeptide sequence selected from the group consisting of:
  - (a) amino acids 1-281 of SEQ ID NO:2 in which 1 to 5 amino acid residues are substituted, deleted or added;
  - (b) amino acids 1-281 of SEQ ID NO:2 in which 5 to 10 amino acid residues are substituted, deleted or added;
  - (c) amino acids 1-38 of SEQ ID NO:2 in which 1 to 5 amino acid residues are substituted, deleted or added;
  - (d) amino acids 1-38 of SEQ ID NO:2 in which 5 to 10 amino acid residues are substituted, deleted or added;
  - (e) amino acids 39-281 of SEQ ID NO:2 in which 1 to 5 amino acid residues are substituted, deleted or added; and
  - (f) amino acids 39-281 of SEQ ID NO:2 in which 5 to 10 amino acid residues are substituted, deleted or added;

wherein said polypeptide sequence has a biological activity selected from the group consisting of:

- (i) binding an antibody specific to the polypeptide of SEQ ID NO:2;
- (ii) inducing apoptosis of a cell line derived from pathologic tissue; and
- (iii) inducing apoptosis of T cells.
- 19. The purified protein of claim 18 wherein said polypeptide sequence is (a).
- 20. The purified protein of claim 18 wherein said polypeptide sequence is (b).
- 21. The purified protein of claim 18 wherein said polypeptide sequence is (c).

- 22. The purified protein of claim 18 wherein said polypeptide sequence is (d).
- 23. The purified protein of claim 18 wherein said polypeptide sequence is (e).
- 24. The purified protein of claim 18 wherein said polypeptide sequence is (f).
- 25. An purified protein produced by a process comprising:

  expressing in a host cell a nucleic acid encoding said protein so as to produce said protein, wherein the nucleic acid is selected from the group consisting of:
  - (a) a polynucleotide encoding amino acids 1 to 281 of SEQ ID NO:2;
  - (b) a polynucleotide encoding amino acids 39 to 281 of SEQ ID NO:2;
  - (c) a polynucleotide encoding amino acids 1 to 281 of SEQ ID NO:2, except for 1 to 5 conservative amino acid substitutions;
  - (d) a polynucleotide encoding amino acids 1 to 281 of SEQ ID NO:2, except for 5 to 10 conservative amino acid substitutions;
  - (e) a polynucleotide encoding amino acids 39 to 281 of SEQ ID NO:2, except for
     1 to 5 conservative amino acid substitutions;
  - a polynucleotide encoding amino acids 39 to 281 of SEQ ID NO:2, except for
     to 10 conservative amino acid substitutions;
  - a polynucleotide encoding the amino acid sequence encoded by the human
     cDNA contained in ATCC Deposit No. 97448; and
  - (h) a polynucleotide that is complementary to a polynucleotide which hybridizes at 60°C in a hybridization buffer consisting of 0.5 X SSC and 0.1% SDS to a polynucleotide selected from the group consisting of:
    - (i) a polynucleotide encoding amino acids 1 to 281 of SEQ ID NO:2;
    - (ii) a polynucleotide encoding amino acids 39 to 281 of SEQ ID NO:2; and
    - (iii) a polynucleotide encoding the amino acid sequence encoded by the human cDNA contained in ATCC Deposit No. 97448, wherein said

polynucleotide encodes a polypeptide that has a biological activity selected from the group consisting of:

- (aa) binding an antibody specific to the polypeptide of SEQ ID NO:2;
- (bb) inducing apoptosis of a cell line derived from pathologic tissue; and
- (cc) inducing apoptosis of T cells.
- 26. The purified protein of claim 25, which comprises a heterologous polypeptide sequence.
- 27. A composition comprising the purified protein of claim 25 and a pharmaceutically acceptable carrier.
- 28. A protein comprising the amino acid sequence of the purified protein of claim 25.
- 29. A protein comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of the purified protein of claim 25, wherein said protein has a biological activity selected from the group consisting of:
  - (a) binding an antibody specific to the polypeptide of SEQ ID NO:2;
  - (b) inducing apoptosis of a cell line derived from pathologic tissue; and
  - (c) inducing apoptosis of T cells.